Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Influenza

Free Subscription Articles published in J Gen Virol Retrieve available abstracts of 58 articles: HTML format

Single Articles

March 2026
1. GROSS J, Pouget B, Sarrat M, Foret-Lucas C, et al
   In vivo inhibition of JAK-STAT signalling enhances high pathogenicity influenza virus replication in ducks.
   J Gen Virol. 2026;107:002238.
   PubMed     Abstract available
   
   
   February 2026
2. KERR HEM, Daniels A, Fletcher SL, Craig N, et al
   RNA interference screen against SARS-CoV-2 identifies proviral vesicular transport factors involved in release.
   J Gen Virol. 2026;107.
   PubMed     Abstract available
   
   
   
3. PAN X, Shi X, Zhao L, Yan D, et al
   Amino acid mutations K54E and S154P in the neuraminidase attenuate H3N2 canine influenza virus in mice.
   J Gen Virol. 2026;107.
   PubMed     Abstract available
   
   
   
4. FARRELL ML, McGrath G, Cuartero LG, Barry G, et al
   Avian influenza in Ireland: a spatiotemporal, subtype and host-based analysis (1983-2024).
   J Gen Virol. 2026;107:002218.
   PubMed     Abstract available
   
   
   January 2026
5. GERODEZ A, Dufrasne FE, Denis O, Steensels M, et al
   The cellular activating protein-1 cFos regulates influenza A virus replication.
   J Gen Virol. 2026;107:002194.
   PubMed     Abstract available
   
   
   December 2025
6. METAXAKI M, Ram R, Perera M, Wills M, et al
   Robust antibody and T cell responses tracked longitudinally in patients with long COVID.
   J Gen Virol. 2025;106:002172.
   PubMed     Abstract available
   
   
   
7. VAN DIEMEN PM, Ramsay AM, Everett HE, Hurley S, et al
   Experimental infection of alpacas (Vicugna pacos) with influenza C or D viruses results in subclinical upper respiratory tract disease.
   J Gen Virol. 2025;106.
   PubMed     Abstract available
   
   
   
8. EASTON V, McPhillie MJ, Santos IA, Hall P, et al
   Identification and characterization of candidate inhibitors of the SARS-CoV-2 nsp14 3'-5' exoribonuclease.
   J Gen Virol. 2025;106.
   PubMed     Abstract available
   
   
   November 2025
9. GIOVANETTI M, Cella E, Soliani L, Prosperi A, et al
   From North to South: transmission dynamics of H1N1pdm09 swine influenza A viruses in Italy.
   J Gen Virol. 2025;106.
   PubMed     Abstract available
   
   
   
10. OHRNBERGER S, Meyer Zu Natrup C, Clever S, Schunemann LM, et al
    Strong immunogenicity and protection against SARS-CoV-2 in hamsters induced by heterologous boost vaccination with an MVA-based COVID-19 vaccine candidate.
    J Gen Virol. 2025;106:002180.
    PubMed     Abstract available
    
    
    
11. ENTRIKEN CG, Bruce KL, Coyne BM, Kruyer SH, et al
    Improved efficacy of an influenza DNA vaccine through high-density microarray patch delivery.
    J Gen Virol. 2025;106:002179.
    PubMed     Abstract available
    
    
    October 2025
12. SHIMOTAI Y, Sugawara K, Matsuzaki Y, Muraki Y, et al
    Cytoplasmic domain of CM2 is involved in the replication of influenza C virus.
    J Gen Virol. 2025;106:002165.
    PubMed     Abstract available
    
    
    September 2025
13. POKHAREL BR, Majumdar N, Williams F, Dickerson A, et al
    SARS-CoV-2 infection of substantia nigra pars compacta induces expression of miR-330-5p at 10 days post-infection.
    J Gen Virol. 2025;106.
    PubMed     Abstract available
    
    
    
14. BILLINGTON E, Di Genova C, Warren CJ, Thomas SS, et al
    Investigating factors driving shifts in subtype dominance within H5Nx clade 2.3.4.4b high pathogenicity avian influenza viruses.
    J Gen Virol. 2025;106:002150.
    PubMed     Abstract available
    
    
    
15. DI GENOVA C, Warren CJ, Johnson S, Riccio S, et al
    Pigeons exhibit low susceptibility and poor transmission capacity for H5N1 clade 2.3.4.4b high pathogenicity avian influenza virus.
    J Gen Virol. 2025;106.
    PubMed     Abstract available
    
    
    
16. PHAN N, Zaytseva Y, Lin CC, Mishra M, et al
    PUM2 binds SARS-CoV-2 RNA and PUM1 mildly reduces viral RNA levels, but neither protein affects progeny virus production.
    J Gen Virol. 2025;106:002152.
    PubMed     Abstract available
    
    
    
17. HA Y, Lee YH, Jo HS, Kwon TW, et al
    Susceptibility of different mouse strains to SARS-CoV-2 spike receptor-binding domain protein-induced lung inflammation: a comparative study.
    J Gen Virol. 2025;106.
    PubMed     Abstract available
    
    
    August 2025
18. BREITINGER U, Zakaria ZIS, Mahgoub HA, Wiessler AL, et al
    Activity and cellular distribution of ORF3a mutants of SARS-CoV-2 variants of concern.
    J Gen Virol. 2025;106:002135.
    PubMed     Abstract available
    
    
    July 2025
19. HIRST JC, Napier A, Burbidge D, Scott K, et al
    Glycan site loss in two egg-adapted live attenuated influenza vaccine strains does not cause antigenic mismatches.
    J Gen Virol. 2025;106.
    PubMed     Abstract available
    
    
    
20. YANG T, Zhu CY, Yu PH, Yang C, et al
    Arsenic trioxide could promote SARS-CoV-2 NSP12 protein degradation.
    J Gen Virol. 2025;106.
    PubMed     Abstract available
    
    
    
21. CHAN JCM, Ching RHH, Kock HHM, Long T, et al
    Evaluation of pandemic potential of the genotype 4 (G4) swine influenza virus using ex vivo and in vitro cultures of the human respiratory tract.
    J Gen Virol. 2025;106:002133.
    PubMed     Abstract available
    
    
    June 2025
22. CAPELASTEGUI F, Goldhill DH
    H5N1 2.3.4.4b: a review of mammalian adaptations and risk of pandemic emergence.
    J Gen Virol. 2025;106:002109.
    PubMed     Abstract available
    
    
    May 2025
23. AHMED MN, Abu Habib US, Abdallah AM, Emara MM, et al
    The impact of pre-existing immunity on the emergence of within-host immune-escape mutations in Omicron lineages.
    J Gen Virol. 2025;106:002108.
    PubMed     Abstract available
    
    
    April 2025
24. SANCHEZ-MARTINEZ A, Moore T, Freitas TS, Benzaken TR, et al
    Recent advances in the prevention and treatment of respiratory syncytial virus disease.
    J Gen Virol. 2025;106.
    PubMed     Abstract available
    
    
    
25. ARANDA AJ, Aguilar-Tipacamu G, Perez DR, Banuelos-Hernandez B, et al
    Emergence, migration and spreading of the high pathogenicity avian influenza virus H5NX of the Gs/Gd lineage into America.
    J Gen Virol. 2025;106:002081.
    PubMed     Abstract available
    
    
    March 2025
26. HANKINSON J, Young D, Wignall-Fleming EB, Lukoszek R, et al
    The Cap-proximal secondary structures of the 5'UTRs of parainfluenza virus 5 mRNAs specify differential sensitivity to type I interferon and IFIT1.
    J Gen Virol. 2025;106.
    PubMed     Abstract available
    
    
    February 2025
27. WEBB I, Erdmann M, Milligan R, Savage M, et al
    Examining the feasibility of replacing ORF3a with fluorescent genes to construct SARS-CoV-2 reporter viruses.
    J Gen Virol. 2025;106:002072.
    PubMed     Abstract available
    
    
    January 2025
28. RANDALL RE, Young D, Pisliakova M, Andrejeva J, et al
    Single-cycle parainfluenza virus type 5 vectors for producing recombinant proteins, including a humanized anti-V5 tag antibody.
    J Gen Virol. 2025;106.
    PubMed     Abstract available
    
    
    December 2024
29. KRISHNA B, Metaxaki M, Perera M, Wills M, et al
    Comparison of different T cell assays for the retrospective determination of SARS-CoV-2 infection.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    
30. ALNAJJAR S, Larios-Mora A, Van-Geelen A, Gallup J, et al
    Therapeutic efficacy of JNJ-49214698, an RSV fusion inhibitor, in RSV-infected neonatal lambs.
    J Gen Virol. 2024;105:002056.
    PubMed     Abstract available
    
    
    November 2024
31. BOE CA, Fiskebeck EMLZ, Reiten MR, Akerstedt J, et al
    Emergence of highly pathogenic avian influenza viruses H5N1 and H5N5 in white-tailed eagles, 2021-2023.
    J Gen Virol. 2024;105:002035.
    PubMed     Abstract available
    
    
    October 2024
32. SAENKHAM-HUNTSINGER P, Drelich AK, Huang P, Peng BH, et al
    BALB/c mice challenged with SARS-CoV-2 B.1.351 beta variant cause pathophysiological and neurological changes within the lungs and brains.
    J Gen Virol. 2024;105:002039.
    PubMed     Abstract available
    
    
    September 2024
33. SHIPLEY R, Seekings AH, Byrne AMP, Shukla S, et al
    SARS-CoV-2 infection and transmission via the skin to oro-nasal route with the production of bioaerosols in the ferret model.
    J Gen Virol. 2024;105:002022.
    PubMed     Abstract available
    
    
    July 2024
34. HAVERTY R, McCormack J, Evans C, Purves K, et al
    SARS-CoV-2 infects neurons, astrocytes, choroid plexus epithelial cells and pericytes of the human central nervous system in vitro.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    
35. JAMES J, Thomas SS, Seekings AH, Mahmood S, et al
    Evaluating the epizootic and zoonotic threat of an H7N9 low-pathogenicity avian influenza virus (LPAIV) variant associated with enhanced pathogenicity in turkeys.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    
36. KING J, Pohlmann A, Bange A, Horn E, et al
    Red knots in Europe: a dead end host species or a new niche for highly pathogenic avian influenza?
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    June 2024
37. BORDES L, Gerhards NM, Peters S, van Oort S, et al
    H5N1 clade 2.3.4.4b avian influenza viruses replicate in differentiated bovine airway epithelial cells cultured at air-liquid interface.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    May 2024
38. AHRENS AK, Jonsson SR, Svansson V, Brugger B, et al
    Iceland: an underestimated hub for the spread of high-pathogenicity avian influenza viruses in the North Atlantic.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    
39. KARA Y, Kizil MC, Iseri Nepesov M, Kacmaz E, et al
    Assessing the change in the epidemiology of seasonal respiratory viruses with the onset of the COVID-19 pandemic.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    February 2024
40. HARDISTY G, Nicol MQ, Shaw DJ, Bennet ID, et al
    Latent gammaherpesvirus infection enhances type I IFN response and reduces virus spread in an influenza A virus co-infection model.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    January 2024
41. HAYES RS, Oraby AK, Camargo C, Marchant DJ, et al
    Mapping respiratory syncytial virus fusion protein interactions with the receptor IGF1R and the impact of alanine-scanning mutagenesis on viral infection.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    
42. SEEKINGS AH, Liang Y, Warren CJ, Hjulsager CK, et al
    Transmission dynamics and pathogenesis differ between pheasants and partridges infected with clade 2.3.4.4b H5N8 and H5N1 high-pathogenicity avian influenza viruses.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    
43. MCMILLAN CLD, Wijesundara DK, Choo JJY, Amarilla AA, et al
    Enhancement of cellular immunity following needle-free vaccination of mice with SARS-CoV-2 spike protein.
    J Gen Virol. 2024;105.
    PubMed     Abstract available
    
    
    December 2023
44. APAA T, Withers AJ, Mackenzie L, Staley C, et al
    Lack of detection of SARS-CoV-2 in British wildlife 2020-21 and first description of a stoat (Mustela erminea) Minacovirus.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    November 2023
45. RANDALL RE, Young DF, Hughes DJ, Goodbourn S, et al
    Persistent paramyxovirus infections: in co-infections the parainfluenza virus type 5 persistent phenotype is dominant over the lytic phenotype.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
46. GRAND RJ
    SARS-CoV-2 and the DNA damage response.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    October 2023
47. PHILIP AA, Hu S, Dai J, Patton JT, et al
    Recombinant rotavirus expressing the glycosylated S1 protein of SARS-CoV-2.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
48. UCHECHUKWU CF, Anyaduba UL, Udekwu CC, Orababa OQ, et al
    Desmoglein-2 and COVID-19 complications: insights into its role as a biomarker, pathogenesis and clinical implications.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
49. JUCKEL D, Desmarets L, Danneels A, Rouille Y, et al
    MERS-CoV and SARS-CoV-2 membrane proteins are modified with polylactosamine chains.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    July 2023
50. THURSZ M, Sadiq F, Tree JA, Karayiannis P, et al
    Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    June 2023
51. OKUYA K, Khalil AM, Esaki M, Nishi N, et al
    Newly emerged genotypes of highly pathogenic H5N8 avian influenza viruses in Kagoshima prefecture, Japan during winter 2020/21.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
52. MIRABELLI C, Bragazzi Cunha J, Wotring JW, Sherman EJ, et al
    ARF6 is a host factor for SARS-CoV-2 infection in vitro.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
53. APAA T, Withers AJ, Staley C, Blanchard A, et al
    Sarbecoviruses of British horseshoe bats; sequence variation and epidemiology.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    May 2023
54. JAMES J, Billington E, Warren CJ, De Sliva D, et al
    Clade 2.3.4.4b H5N1 high pathogenicity avian influenza virus (HPAIV) from the 2021/22 epizootic is highly duck adapted and poorly adapted to chickens.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
55. DE BUHR H, de Leeuw OS, Harders F, Peeters BP, et al
    Emergence of biased hypermutation in a heterologous additional transcription unit in recombinant lentogenic Newcastle disease virus.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
56. SULLIVAN DJ, Franchini M, Senefeld JW, Joyner MJ, et al
    Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    April 2023
57. SKOG E, Nykvist M, Naguib MM, Wille M, et al
    An oseltamivir-resistant avian H1N1 influenza A virus can transmit from mallards to chickens similarly to a wild-type strain: implications for the risk of resistance transmission to humans.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
58. WOO PCY, de Groot RJ, Haagmans B, Lau SKP, et al
    ICTV Virus Taxonomy Profile: Coronaviridae 2023.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum